(Q39021781)

8 September 2017

1 reference

title

Safety concerns and risk management of multiple sclerosis therapies (English)

1 reference

8 September 2017

0 references

P Soelberg Sorensen

1

1 reference

PubMed ID

27891572

8 September 2017

language of work or name

English

0 references

publication date

27 November 2016

1 reference

Acta Neurologica Scandinavica

8 September 2017

1 reference

8 September 2017

136

1 reference

8 September 2017

3

1 reference

8 September 2017

168-186

1 reference

New management algorithms in multiple sclerosis

8 September 2017

1 reference

Principles of a new treatment algorithm in multiple sclerosis

21 January 2018

1 reference

Gene expression analysis of interferon-beta treatment in multiple sclerosis

21 January 2018

1 reference

Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study

21 January 2018

1 reference

Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.

21 January 2018

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance

21 January 2018

1 reference

Mechanisms of action of glatiramer acetate in multiple sclerosis

21 January 2018

1 reference

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

Mitoxantrone and cytotoxic drugs' mechanisms of action

21 January 2018

1 reference

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

Mitoxantrone: benefits and risks in multiple sclerosis patients

21 January 2018

1 reference

Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

21 January 2018

1 reference

Immune mechanisms of new therapeutic strategies in MS: teriflunomide

21 January 2018

1 reference

Randomized trial of oral teriflunomide for relapsing multiple sclerosis.

21 January 2018

1 reference

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

21 January 2018

1 reference

Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.

21 January 2018

1 reference

Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis

21 January 2018

1 reference

Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years

21 January 2018

1 reference

Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis

21 January 2018

1 reference

BG-12 in multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

21 January 2018

1 reference

Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis

21 January 2018

1 reference

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

21 January 2018

1 reference

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

21 January 2018

1 reference

Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.

21 January 2018

1 reference

Overview and safety of fingolimod hydrochloride use in patients with multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

First-dose effects of fingolimod: Pooled safety data from three phase 3 studies

21 January 2018

1 reference

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

21 January 2018

1 reference

Oral fingolimod (FTY720) for relapsing multiple sclerosis

21 January 2018

1 reference

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

21 January 2018

1 reference

Fingolimod-associated macular edema: incidence, detection, and management

21 January 2018

1 reference

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

21 January 2018

1 reference

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

21 January 2018

1 reference

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab

21 January 2018

1 reference

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

21 January 2018

1 reference

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

21 January 2018

1 reference

Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab

21 January 2018

1 reference

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.

21 January 2018

1 reference

L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

21 January 2018

1 reference

Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab

21 January 2018

1 reference

Successful management of natalizumab-associated progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient with multiple sclerosis

21 January 2018

1 reference

Immune reconstitution inflammatory syndrome in natalizumab-associated PML.

21 January 2018

1 reference

Treatment of relapsing-remitting multiple sclerosis after 24 doses of natalizumab: evidence from an Italian spontaneous, prospective, and observational study (the TY-STOP Study).

21 January 2018

1 reference

Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis

21 January 2018

1 reference

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial

21 January 2018

1 reference

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

21 January 2018

1 reference

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

21 January 2018

1 reference

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

21 January 2018

1 reference

Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy

21 January 2018

1 reference

Predicting autoimmunity after alemtuzumab treatment of multiple sclerosis.

21 January 2018

1 reference

Intrathecal effects of daclizumab treatment of multiple sclerosis

21 January 2018

1 reference

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

21 January 2018

1 reference

CD20-targeted therapy: the next generation of antibodies

21 January 2018

1 reference

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

21 January 2018

1 reference

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

21 January 2018

1 reference

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study

21 January 2018

1 reference

Sphingosine 1-phosphate receptor modulators in multiple sclerosis

21 January 2018

1 reference

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/ANE.12712

1 reference

8 September 2017

1 reference

PubMed ID

27891572